Resumen
Recently, significant breakthroughs have been made in the medical treatment of advanced hepatocellular carcinoma (HCC). There is no consensus on whether adjuvant therapy is necessary after curative surgery for HCC. However, some patients still face a high risk of recurrence. Consequently, researchers have been exploring adjuvant therapies, such as chemotherapy, targeted therapy, and immunotherapy, to mitigate the risk of recurrence and improve patient prognosis. Although there is ongoing debate regarding the necessity of adjuvant therapy after surgery, examining the literature and investigating risk factors for high recurrence and the efficacy of current treatments can provide clinicians with more comprehensive information to develop individualized treatment plans. Moreover, advancements in future research and clinical practice will enhance our understanding and treatment of high recurrence in HCC.